<DOC>
	<DOCNO>NCT00893867</DOCNO>
	<brief_summary>The purpose trial determine intravenous administration metal ion trap agent DP-b99 9 hour follow acute ischemic stroke onset , 3 additional day ( 4 consecutive day total ) effective improve long term outcome . Patients follow 3 month stroke .</brief_summary>
	<brief_title>Efficacy Safety Study DP-b99 Treating Acute Ischemic Stroke</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter , multi-national , parallel-arm , pivotal study compare placebo group DP-b99 group treat intravenous 1.0 mg/kg/d 4 consecutive day , acute ischemic stroke patient entry National Institutes Health Stroke Scale ( NIHSS ) score 10-16 clinical syndrome include least 1 follow : language dysfunction , visual field defect Extinction Inattention ( formerly Neglect ) ( reflect least 1 point correspond item NIHSS : 9 , 3 11 ) . An interim analysis futility perform Day 90 ( last available observation ) primary endpoint data collect 45 % subject plan enrol . Clinical trial material ( CTM ) administer within 9 hour onset acute ischemic stroke symptom . Subjects randomize ratio 1:1 receive either DP-b99 placebo . A data safety monitor board ( DSMB ) ass accumulate safety data periodically oversee interim futility analysis .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Inclusion criterion : 1 . M F age 18 85 , inclusive 2 . Suffered acute , likely hemispheric , ischemic stroke , define acute , focal , neurological deficit ( ) , secondary presume vascular event , must include least one follow component ( reflect least 1 point correspond item NIHSS : 3 , 9 11 ) : Visual Best Language Extinction Inattention ( formerly Neglect ) 3 . Suffered onset acute ischemic stroke evaluate treatment initiate within 9 hour onset acute ischemic stroke symptom . 4 . Screening NIHSS score 10 16 , inclusive 5 . Readily accessible peripheral venous access clinical trial material ( CTM ) administration blood sample 6 . Ability understand requirement study willing provide write informed consent evidence signature inform consent document approve institutional review board independent ethic committee , agree abide study restriction return required assessment . 7 . Provided write authorization use disclosure protect health information accordance Health Insurance Portability Accountability Act United States Personal Information Protection Electronic Documents Act Canada 1 . An intracerebral subarachnoid hemorrhage per screening/baseline computerize tomography scan susceptibilityweighted magnetic resonance image 2 . A candidate either : 1. thrombolytic therapy , treat thrombolytic therapy current stroke 2. mechanical thromboembolectomy , treat mechanical thromboembolectomy current stroke 3 . Delirious , comatose stuporous demented , mental impairment investigator 's opinion render subject incapable participate study 4 . Have seizure ( ) anytime stroke onset screening/baseline NIHSS evaluation 5 . Neurological nonneurological comorbidities investigator 's opinion may lead , independent current stroke , deterioration subject 's neurological status trial period , may render study 's neurological assessment inconclusive purpose evaluate solely stroke 's effect 6 . Likely undergo procedure involve cardiopulmonary bypass study period 7 . Suffered myocardial infarction last 90 day 8 . Any medical condition investigator 's opinion may threaten subject 's ability complete study ( e.g. , concurrent significant lifethreatening disease , malignancy end stage organ failure ) 9 . Rapid spontaneous improvement neurological sign screening/baseline assessment 10 . Premorbid neurological deficit functional limitation assess prestroke Modified Rankin Scale score &gt; 1 11 . Suffered stroke within 90 day screening/baseline assessment either diagnostically confirm assumed cerebral territory current acute stroke 12 . Either severe hypertension hypotension , measure least 2 consecutive supine measurement take 10 minute apart prior randomization . 13 . Significant current renal hepatic disease ( ) : serum creatinine concentration &gt; 2.5 mg/dL ; alanine aminotransferase , aspartate aminotransferase , gammaglutamyl transferase value three time great upper limit normal . 14 . Have platelet count &lt; 100,000/mm3 , patient oral anticoagulant study entry , INR &gt; 4 15 . Female childbearing potential willing use adequate effective birth control measure duration trial . Effective birth control measure include hormonal contraception , barrier method diaphragm , intrauterine device and/or condom spermicide 16 . Positive urine pregnancy test screening/baseline lactate female 17 . Currently dependent , abuse , alcohol one following : sympathomimetic amine , cannabis , cocaine , hallucinogen , inhalant , opioids , phencyclidine , sedatives hypnotic 18 . Received investigational drug product participate investigational drug study within period 30 day prior receive study medication previously participate clinical trial involve DPb99 19 . Severe anemia measure hemoglobin value &lt; 7 g/dl . 20 . In dependent relationship physician study sponsor . 21 . Known hypersensitivity component investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>acute ischemic stroke</keyword>
	<keyword>neuroprotective agent</keyword>
</DOC>